Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

Lynne H. Morrison

doi:10.1016/j.jaad.2004.06.007

Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

Lynne H. Morrison

Dermatology

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Abstract

Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

Original language	English (US)
Pages (from-to)	817-819
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	51
Issue number	5
DOIs	https://doi.org/10.1016/j.jaad.2004.06.007
State	Published - Nov 2004

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2004.06.007

Cite this

@article{d53e5ce6f1334d5cb8a6b4b13a5c9dae,

title = "Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)",

abstract = "Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.",

author = "Morrison, {Lynne H.}",

year = "2004",

month = nov,

doi = "10.1016/j.jaad.2004.06.007",

language = "English (US)",

volume = "51",

pages = "817--819",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

AU - Morrison, Lynne H.

PY - 2004/11

Y1 - 2004/11

N2 - Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

AB - Three patients with refractory pemphigus vulgaris improved after rituximab, an anti-CD20 monoclonal antibody directed against B cells. Treatment was well tolerated immediately, but one patient developed fatal pneumocystis carinii pneumonia. Serious infections have occurred in several pemphigus patients treated with rituximab and immunosuppressive medications, warranting further evaluation of risk-benefit ratio.

UR - http://www.scopus.com/inward/record.url?scp=8744228329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744228329&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2004.06.007

DO - 10.1016/j.jaad.2004.06.007

M3 - Article

C2 - 15523367

AN - SCOPUS:8744228329

SN - 0190-9622

VL - 51

SP - 817

EP - 819

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -

Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this